35: Troll of Transplantation Part 2

This podcast addresses the complexities of managing Cytomegalovirus (CMV) in transplant patients, particularly focusing on resistant and refractory cases. Dr. Camille Kotton, an expert in transplant ID, explains that CMV DNAemia levels may not immediately decrease after antiviral treatment starts, as the test measures DNA presence rather than live virus count. The discussion covers defining resistant CMV, emphasizing clinical presentation alongside viral load, and recommends resistance testing around weeks 2-4 if improvement isn't observed. Key strategies include reducing immunosuppression and ensuring correct antiviral dosing to prevent resistance. Dr. Kotton also highlights promising future developments such as new drugs like Moribivir and potential CMV vaccines, which could revolutionize treatment approaches.